^
BIOMARKER:
Chr del(11q)
Chr del(11q)
CLL
zanubrutinib
Sensitive
:
C3
EHA 2021 - 4d
Chr del(11q)
CLL
ibrutinib
Sensitive
:
A2
Chr del(11q)
CLL
rituximab
Resistant
:
A2
Chr del(11q)
CLL
obinutuzumab + acalabrutinib
Sensitive
:
A2
Chr del(11q)
CLL
ibrutinib + ublituximab
Sensitive
:
B
Chr del(11q)
CLL
venetoclax
Sensitive
:
C2
Chr del(11q)
CLL
lenalidomide + tafasitamab
Sensitive
:
C3
Chr del(11q)
CLL
RP6530
Sensitive
:
C3
Chr del(11q)
Small Lymphocytic Lymphoma
ICP-022
Sensitive
:
C3
Chr del(11q)
CLL
ICP-022
Sensitive
:
C3
Chr del(11q)
CLL
venetoclax + ibrutinib
Sensitive
:
C3
Chr del(11q)
Multiple Myeloma
obinutuzumab
Resistant
:
C3
Chr del(11q)
CLL
duvelisib
Sensitive
:
C3
Chr del(11q)
CLL
FCR
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our